Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
df1001 (1 trial)
df6002 (1 trial)
df9001 (1 trial)
nivolumab (opdivo) (1 trial)
pembrolizumab (keytruda) (2 trials)
df6215 (1 trial)
Carcinoma (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Melanoma (Phase 2)
Neoplasms (Phase 2)
Trials (4 total)
Trial APIs (6 total)